CAS 936446-61-6

NRC-2694

CAS : 936446-61-6

Formule : C₂₄H₂₆N₄O₃

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 418.4882

Ref: IN-DA01EO8C

N-(3-Ethynylphenyl)-7-Methoxy-6-(3-Morpholinopropoxy)Quinazolin-4-Amine

CAS : 936446-61-6

N-(3-Ethynylphenyl)-7-Methoxy-6-(3-Morpholinopropoxy)Quinazolin-4-Amine

Degré de pureté : 99%

Masse moléculaire : 418.49g/mol

Ref: 54-OR1025980

NRC-2694

CAS : 936446-61-6

NRC-2694

Degré de pureté : ≥98%

Masse moléculaire : 418.49g/mol

Ref: 54-BUP09435

NRC-2694

CAS : 936446-61-6

NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.

Formule : C₂₄H₂₆N₄O₃

Degré de pureté : 99.90%

Couleur et forme : Solid

Masse moléculaire : 418.49

Ref: TM-T16343

NRC-2694

CAS : 936446-61-6

NRC-2694 is a novel anilino-based oral solid formulation for the treatment of bladder cancer. NRC-2694 is designed to inhibit the growth of cells in the bladder by binding to them and preventing their division. This drug has shown a safety profile in animal studies and has been shown to be active against squamous cell carcinomas in mice. The drug was also tested in vivo with bioavailability data in rats, showing that it is absorbed through the gastrointestinal tract and distributed throughout the body.

Formule : C₂₄H₂₆N₄O₃

Degré de pureté : Min. 95%

Masse moléculaire : 418.49 g/mol

Ref: 3D-LMB44661